Raymond James resumed coverage of Disc Medicine (IRON) with a Strong Buy rating and $89 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS – probability of success – lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the company, the firm believes that as the first disease-modifying agent to treat EPP/XLP, Disc Medicine can deliver on $1B ore more in bitopertin sales with about 30%-35% penetration of the initial 6K focus EPP population, Raymond James added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine’s Promising Potential in Myelofibrosis Anemia Treatment: Analyst Highlights Unique Mechanism and Market Opportunity
- Disc Medicine price target raised to $120 from $112 at BMO Capital
- Disc Medicine’s Promising Position in MF Anemia Treatment: Buy Rating Affirmed by Evan Seigerman
- Promising Outlook for Disc Medicine’s DISC-0974 in Anemia Treatment Justifies Buy Rating
- Disc Medicine Reports Strong Q1 2025 Progress